Age

12–85

Sex

ALL

Healthy volunteers

Not accepted

Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.
Onset of GBS-related weakness ≤10 days before start of infusion on Day 1
GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.

Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.
Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.
Other protocol-defined criteria may apply.

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)